Biotech policy debates should account for patients seeking Phase I access

For some patients, access to an early clinical trial abroad can be a life-changing medical option rather than an abstract geopolitics issue

In the current debate around biotech and China, too little attention is given to actual patients. This isn't just about biotech: it's about patients, for whom access to a Phase I trial can be life-changing. I have recently interviewed an